An announcement from Edgewise Therapeutics (EWTX) is now available.
Edgewise Therapeutics, Inc. has appointed Arlene Morris as a Class I director and member of its Audit and Compensation Committees, taking over from Peter Thompson. Bringing decades of biotech leadership and consultancy experience, Morris’s appointment follows Kenneth Harrison’s resignation. Recognized for her independence and financial literacy, she will receive a standard compensation package, including cash retainers and a significant stock option that fully vests in the event of a control change. No disclosure conflicts were reported.
See more data about EWTX stock on TipRanks’ Stock Analysis page.
